Press Releases

<< Back

2019

October 11

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

October 04

Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting

October 03

Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

September 09

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

August 27

Molecular Partners reports key financials for H1 19 and corporate highlights: EMA has validated the marketing authorization application for abicipar; Focus of MP0250 on multiple myeloma with expected initiation of ph2 IMiD trial in Q4 19; MP0310 ph1 start on track for H2 19

August 08

Molecular Partners Announces Appointment of Nicolas Leupin, M.D., MBA, as Chief Medical Officer

August 06

Molecular Partners’ strategic partner Allergan announced today that EMA has validated the marketing authorisation application for abicipar

June 11

Molecular Partners Announces Scientific Leadership Transition After Successful Transformation of Research Organization to Focus on Novel DARPin® Therapeutics in Oncology

May 09

INTERIM STATEMENT BY MANAGEMENT – Q1 2019: Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative oncology DARPin® candidates presented; Recruitment hold in MP0250 NSCLC trial; Ongoing focus on multiple myeloma for MP0250 clinical development

April 16

Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting

April 02

Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol

March 29

Molecular Partners to present pre-clinical data on its FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) at the AACR 2019

March 19

Molecular Partners Publishes Invitation to Annual General Meeting 2019

March 15

Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018

March 11

Molecular Partners to present at the Cowen and Company 39th Annual Healthcare Conference

February 07

Molecular Partners reports key financials for FY 2018 and corporate highlights for Q4 2018

January 07

Molecular Partners to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018

December 19

Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-oncology

December 06

Molecular Partners’ R&D Day in New York highlights progress of pipeline of DARPin® therapeutic candidates and dedicated research focus areas

November 06

Molecular Partners to Present New Data on Immuno-Oncology Pipeline at Upcoming Scientific Conferences

November 01

Positive phase 3 efficacy data for abicipar, ongoing clinical trials for MP0250 in oncology and further advancement of I/O pipeline

October 29

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic

August 30

Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented

July 19

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration

June 21

Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company

June 15

Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm

May 16

Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018

April 26

Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds

April 21

Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin

April 18

Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting – Bill Burns elected new Chairman

April 11

Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC

April 05

Molecular Partners to present MP0310 pre-clinical data and MP0250 clinical abstracts at the AACR Annual Meeting 2018

March 21

Molecular Partners Publishes Invitation to Annual General Meeting 2018

March 16

Molecular Partners Publishes Audited Financial Results and Annual Report 2017

March 06

Molecular Partners to Present at the Cowen and Company 38th Annual Healthcare Conference

February 19

Molecular Partners’ collaboration partner Allergan exercises the third option for a DARPin® product candidate in ophthalmology

February 08

Molecular Partners reports significant progress of pipeline and preliminary unaudited key financials for 2017 – Key value inflection points in 2018

January 08

Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma

January 04

Molecular Partners to Present at the 36th Annual J.P. Morgan Healthcare Conference

January 03

Molecular Partners’ collaboration partner Allergan exercises options for two DARPin® product candidates

2017

November 09

Molecular Partners expands and advances robust pipeline of DARPin® therapies in oncology and ophthalmology

October 31

Shareholders of Molecular Partners approved the elections of Bill Burns and Patrick Amstutz to the Board of Directors

October 26

Interim Management Statement Q3 2017: Significant progress across all clinical programs – New pre-clinical immuno-oncology data to be presented during R&D Day in New York

October 12

First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274

October 09

Molecular Partners Publishes Invitation to Extraordinary General Meeting to be held on October 31, 2017

October 03

Bill Burns nominated for election to Molecular Partners’ Board of Directors as Vice-Chairman with nomination to Chairman in 2018

September 19

Invitation to R&D Update of Molecular Partners AG on The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics

September 07

Molecular Partners to present at the Morgan Stanley Global Healthcare Conference in New York

August 30

Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead

May 30

Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

May 12

Patrick Amstutz Appointed as Chief Executive Officer

May 11

Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting – Gwen Fyfe elected new Board member

May 09

Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies

May 04

Quarterly Management Statement for the Period Ending March 31, 2017

April 13

Molecular Partners Publishes Invitation to Annual General Meeting 2017

April 12

Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017

April 06

Molecular Partners discloses change in shareholder base

March 31

Molecular Partners Publishes Audited Financial Results and Annual Report 2016

March 01

MOLECULAR PARTNERS TO PRESENT AT THE COWEN AND COMPANY 37th ANNUAL HEALTHCARE CONFERENCE

February 09

Gwen Fyfe, MD, to be proposed for election to Board of Directors at the next Annual General Meeting on May 11, 2017

February 09

Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas – Ongoing strong cash position

January 04

Molecular Partners to Present at the 35th Annual J.P. Morgan Healthcare Conference

2016

November 10

Molecular Partners to Present at the Jefferies 2016 London Healthcare Conference

November 07

Molecular Partners Announces Management Change

November 07

A message from Christian Zahnd

October 27

Quarterly Management Statement for the Perios Ending September 30, 2016

October 15

Abicipar Pegol PALM Study Phase 2 Data in Diabetic Macular Edema (DME) Presented at 2016 AAO Annual Meeting

October 10

Molecular Partners’ Strategic Partner Allergan to Present Abicipar Phase 2 Data of PALM Study in Diabetic Macular Edema (DME) at the 2016 AAO Annual Meeting

October 09

Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies

October 06

Molecular Partners Regains Rights to Multi-DARPin® Drug Candidate Targeting IL-13 & IL-17 for Pulmonary Indications from Janssen

September 28

Molecular Partners to Present the Completed Phase I Dose Escalation Interim Results of MP0250 at the Annual ESMO Congress in Copenhagen

September 07

Molecular Partners to Present at the Morgan Stanley Global Healthcare Conference in New York

September 01

Molecular Partners reports unaudited half-year results for 2016: A period of continued progress for Molecular Partners

July 19

BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders

May 20

Molecular Partners to Present at the UBS Global Healthcare Conference 2016 in New York

May 09

Molecular Partners to Present at the 17th Annual Meeting of Bio€quity Europe 2016 in Copenhagen

April 28

Quarterly Management Statement for the Period Ending March 31, 2016

April 20

Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting – Jeffrey H. Buchalter elected new Board member

April 14

Molecular Partners AG announces successful completion of placement of shares

April 13

Molecular Partners AG upsizes the proposed placement to CHF 30,000,000 based on strong demand and a significant anchor order from a specialist US investor

April 13

Molecular Partners AG Announces Launch of Placement of Shares

March 17

Molecular Partners Publishes Audited Financial Results and Annual Report 2015

March 07

Molecular Partners Reveals Programs in Immuno-Oncology

March 07

Molecular Partners to Present at the Cowen and Company 36th Annual Healthcare Conference

February 04

Molecular Partners reports unaudited financial results for 2015

January 12

Molecular Partners to present at the 34th Annual J.P. Morgan Healthcare Conference

January 08

Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma

2015

December 10

Molecular Partners received a European Small and Mid-Cap Award

November 07

Preliminary Phase I Results Demonstrate Potential Utility of DARPins in Anticancer Treatment

October 29

Quarterly Management Statement for the Period Ending September 30, 2015

October 27

First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference

October 07

Molecular Partners Receives European Biotechnica Award 2015

September 02

Molecular Partners 1H 2015 Release

August 18

Corporate Update

July 24

Molecular Partners confirms its focus on proprietary oncology pipeline – discovery alliance with Roche discontinued

July 21

Allergan strengthens DARPin development and discovery alliance with Molecular Partners

July 07

First patient enrolled in phase III study of abicipar – Molecular Partners receives USD 15 million milestone payment

May 11

Actavis confirms timeline for the start of phase III development of abicipar

May 06

Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting

March 17

Molecular Partners reports its results for the Financial Year 2014 – A transformative year for the company

March 17

Molecular Partners AG announces Andreas Harstrick, M.D., as its Chief Medical Officer

March 10

Corporate Update

March 02

Molecular Partners to present at the Cowen and Company 35th Annual Healthcare Conference

January 13

Molecular Partners to Present at the 33rd Annual J.P. Morgan Healthcare Conference (webcast link included)

2014

December 09

Execution of option by Janssen in multispecific DARPin collaboration

December 05

Total offer size of IPO reaches CHF 106.2 million

November 04

IPO successfully priced post re-launch

November 03

IPO bookbuilding resumes

October 21

Molecular Partners puts IPO on hold

October 08

Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share

September 23

Molecular Partners launches IPO on SIX Swiss Exchange

September 22

FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014

September 19

Appointment of Steven Holtzman as independent board member

July 01

Positive Top-Line Data Reported from Phase 2 Study for DARPin abicipar pegol in wet AMD

2013

December 04

Molecular Partners and Roche enter into alliance to develop new cancer treatments

January 17

Molecular Partners announces publication of its clinical phase I/II trial of MP0112 in DME

2012

November 12

Zurich-Schlieren, Switzerland / Ingelheim, Germany, 12 November 2012

August 21

Allergan and Molecular Partners Enter into Exclusive Alliance

2011

December 08

Molecular Partners Announces Collaboration with Janssen

May 04

Allergan and Molecular Partners enter into a license agreement for MP0112

April 28

Molecular Partners reports positive results from its first clinical studies

2010

September 01

Molecular Partners has been selected as a WEF Technology Pioneer

June 29

Molecular Partners appoints Göran Ando as independent non executive board member

April 30

MP Progresses DARPin into First-In-Humans Clinical Studies

2009

December 15

MP secures CHF 46 million in a Series B financing

May 14

MP reaches all research milestones in collaboration

2008

January 15

MP collaborates with Centocor Research & Development Inc.

2007

November 08

Molecular Partners Appoints Jörn Aldag as Chairman of the Board

August 14

MP secures CHF 18.5 million in Series A Financing

April 18

MP appoints Andreas Emmenegger as Chief Financial Officer

February 28

MP and Roche start collaboration on the DRP Technology

2006

November 30

MP and Schering collaborate in oncology

July 26

MP gains access to ribosome display

2005

February 15

Swiss Technology Award 2005